Last mentioned: Mar 11, 2026
Market Milestone
Global nanomedicine market projected to surpass the $550 billion mark.
Regulatory Maturity
Anticipated standardization of regulatory pathways for nanosimilars and complex nano-formulations.
Pipeline Expansion
Increased R&D focus on non-vaccine applications, particularly in targeted oncology and neurology.
LNP Validation
Global rollout of mRNA vaccines validates lipid nanoparticle delivery at a massive scale.
A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
The global nanomedicine market is projected to exceed $550 billion by 2034, driven by rapid advancements in targeted drug delivery and precision therapeutics. This growth reflects a fundamental shift in how chronic diseases, particularly oncology and cardiovascular conditions, are treated at the molecular level.
This page surfaces every story mentioning DelveInsight Business Research LLP across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where DelveInsight Business Research LLP was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |